Is GIP agonism or antagonism the metabolically useful direction?

The receptor pharmacology I can follow; the in vivo translation is where I lose the thread.

I would like the axes of comparison first and the recommendation second.

I have tried the first option and it works; the question is whether the second is better rather than merely different.

What is the actual trade-off, and does it matter at the scale I am working at?

Mechanically, the receptor is expressed in adipose tissue as well as islet and brain, which is the basis for most of the competing explanations.

The GIP receptor is also expressed in bone and in the vasculature, which raises questions the current trial programme was not designed to answer.

On the detail: receptor heterodimerisation between the two incretin receptors has been proposed and would complicate any account built on the two receptors acting independently.

Adipose GIP receptor function in postprandial lipid handling is established from tracer studies and is the reason the older obesogenic hypothesis was plausible.

Research-use compounds are not approved for human use, and an unsettled mechanism is a poor basis for self-experiment.

Cite SURPASS-2 for the head-to-head and nothing else for it.

edited 15 Mar 2026 by Dr_Ilse_Vandenberg — fixed an arithmetic slip in the third paragraph

Answering this needs the distinction between acute and chronic receptor engagement, because sustained agonism can produce functional desensitisation that resembles antagonism.

GIP receptor agonism appears to reduce nausea signalling in preclinical work, which would mean the GIP limb of a dual agonist improves tolerability and thereby permits higher GLP-1 exposure. That is a mechanistically satisfying explanation and is not yet established in humans.

In healthy physiology GIP contributes more of the incretin effect than GLP-1 does. In type 2 diabetes the GIP insulinotropic response is substantially blunted and partially recoverable with improved glycaemic control, which reframes it as a consequence of the disease rather than a fixed property.

The blunted GIP response in type 2 diabetes is a long-standing finding from infusion studies and predates any therapeutic interest in the receptor.

The clinical result is solid; the mechanism is open. Say both.

The short version: dual agonism produces greater weight and glycaemic effects than GLP-1 agonism alone at comparable exposures, and the mechanism for the weight component is still argued about.

Head-to-head, the dual agonist produced larger HbA1c and weight reductions than semaglutide 1 mg in SURPASS-2, which is the direct comparison usually being invoked.

Preclinical work supporting reduced nausea signalling through GIP receptor agonism is published and is currently the most attractive explanation for the tolerability observations.

Tolerability may be the mechanism by which the second receptor helps, which would be an unglamorous and important answer.

The paradox worth knowing is that both GIP agonists and GIP antagonists reduce body weight in preclinical models, which is a real finding and not a reporting error.

Tirzepatide is a single peptide engineered for imbalanced dual agonism, more potent at GIP than at GLP-1 in receptor terms; the balance is a design parameter rather than an accident.

The structural basis of semaglutide’s pharmacokinetics — Aib-8, the Arg34Lys substitution and the C18 diacid–AEEA linker at Lys26 — is described in the original medicinal chemistry publication, and it is worth reading once because it makes the design logic explicit[1].

Blunted GIP response in diabetes is the historical reason the receptor was overlooked.